Shukra Pharmaceuticals Lists on NSE, Trading Begins Aug 14
Shukra Pharmaceuticals Limited (BSE: 524632) has announced its direct listing and commencement of trading on the National Stock Exchange (NSE) Main Board, effective August 14, 2026. The company will continue to trade on the BSE, adopting a dual-listing strategy to enhance visibility, attract a wider investor base, and improve market liquidity. The NSE trading symbol is SHUKRAPHAR, with ISIN INE551C01044. The base reference price is derived from the BSE closing price on August 13, 2026. Managing Director Dakshesh Shah highlighted this as a significant milestone reflecting strong financial health and operational scaling, aiming to position the company as a premier name in global pharmaceutical manufacturing. Shukra Pharmaceuticals manufactures generic pharmaceutical formulations including tablets, capsules, and liquid injections.
Key Highlights
- Shukra Pharmaceuticals achieves direct listing on NSE Main Board.
- Dual-listing aims to boost visibility and market liquidity.
- Trading commences on August 14, 2026, with symbol SHUKRAPHAR.
- Company manufactures generic pharmaceutical formulations.
- Listing reflects strong financial health and operational scaling.
Price Impact
More from SHUKRAPHAR